ViiV said it will begin shipping Apretude to wholesalers and specialty distributors in the US in early 2022, and will price the drug at $3,700 per dose, which is in the same ballpark as the ...

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi ...

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...

(RTTNews) - GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced the completion of negotiations with the pan-Canadian Pharmaceutical Alliance or pCPA for APRETUDE for pre-exposure ...

Another drugmaker, Viiv Healthcare, also left out most of Latin America when it allowed generics of its HIV prevention shot in about 90 countries. Sold as Apretude, the bi-monthly shots are about ...

Please report side effects. See the full CMI for further details. 1. What is APRETUDE and what is it used for? APRETUDE contains the active ingredient cabotegravir, which belongs to a group of ...

It is safe for a person to take alongside gender affirming hormones. Truvada, Descovy, and Apretude are PrEP medications that are safe to take alongside gender affirming hormone therapy.

The third option is a long-acting injectable medication called Apretude. If you decide to get on PrEP, you will talk with your doctor about which of these three products is best for you. You may want ...